Loading patent…
AssigneeGenmab B.V.
InventorsMarije OVERDIJK, Kristin STRUMANE, Rik RADEMAKER, Esther BREIJ, Janine SCHUURMAN, Paul PARREN
Estimating the term…
The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
An antibody comprising a Fc region of a human immunoglobulin IgG and an antigen binding region binding to human DR5, wherein the Fc region comprises a mutation of an amino acid position corresponding to E430, E345 or S440 in human IgG1, wherein the numbering is according to the EU Index.
Dependencies are inferred from the claim text.